Signal Transduction and Targeted Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2020-05-19 jixiangruyi

秒拒

116 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2020-12-08 1231fb0bm60暂无昵称

综述是不是比研究性论文审稿快呀？

93 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2020-09-04 a201061519

已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？

124 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2022-11-17 1471eab0m84暂无昵称

请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?

192 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2021-10-11 cewei

大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。

303 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2021-06-11 志志呀

投稿11天被拒，着急的人慎投

82 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2021-01-15 ms8406716658181247

2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰

125 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2019-11-27 146a7b84m13(暂无昵称)

同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表:
你的怎么样了，意见回来了吗？

yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？

132 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2023-04-21 爱的哥尔摩来自Baden-Wurttemberg

偏重的研究方向：肿瘤
经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？

329 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=591217, encodeId=adac59121ebc, content=秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9cfd1625038, createdName=jixiangruyi, createdTime=Tue May 19 00:00:00 CST 2020, time=2020-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906203, encodeId=d8e3906203cf, content=综述是不是比研究性论文审稿快呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22172385069, createdName=1231fb0bm60暂无昵称, createdTime=Tue Dec 08 23:55:10 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882791, encodeId=e531882e91d1, content= 已投稿第七天，现在是Manuscript Under Consideration状态。请问是已经送审还是未送审呢？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221030/c5a5f92eeaa6438f9470120d9a013f6f/3a668fe12116417ba59aeafa300cd23b.jpg, createdBy=5a711629755, createdName=a201061519, createdTime=Fri Sep 04 21:17:42 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101123, encodeId=8e382101123ef, content=请问中过的研友，这个杂志是不是编辑给了修稿的机会，就有很大概率接受?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=891b5192912, createdName=1471eab0m84暂无昵称, createdTime=Thu Nov 17 15:32:59 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=303, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916979, encodeId=accd9169e99a, content=2021-01-15 各位老师我也投了sttt 想求助问一下，大editor审稿要多久啊？昨天晚上通知初评过了。给大editor，评估去了。不知道要等多久？非常感谢各位哦！打扰, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210203/3cbf68a0d92f4bbaacf574625e6155ce/fe60014b956f4e4c9543e1281f89b68c.jpg, createdBy=3b4e5080304, createdName=ms8406716658181247, createdTime=Fri Jan 15 19:35:37 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580547, encodeId=cbba58054ed5, content=同问，投出去23天了，还在under consideration，好捉急哇yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, beContent=yyyanz 2019-11-27 00:00:00 发表: 你的怎么样了，意见回来了吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8b25156067, createdName=146a7b84m13(暂无昵称), createdTime=Wed Nov 27 00:00:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127573, encodeId=1835212e57375, content=偏重的研究方向：肿瘤 经验分享：这本期刊和Cell Research、Cell Discovery相比如何，谁的未来潜力更大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=329, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e872037104, createdName=爱的哥尔摩, createdTime=Fri Apr 21 23:55:02 CST 2023, time=2023-04-21, status=1, ipAttribution=Baden-Wurttemberg), GetPortalCommentsPageByObjectIdResponse(id=2089970, encodeId=ebca20899e099, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c06e2073321, createdName=1511f09776m, createdTime=Fri Sep 23 16:26:26 CST 2022, time=2022-09-23, status=1, ipAttribution=)]

2022-09-23 1511f09776m

审稿速度:1.0 | 投稿命中率:5.0
经验分享：刚接收一篇，4个审稿人意见都很专业，有2个明显是领域专家，大修一轮小修一轮，前前后后一共补了半年实验

239 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务